1 / 22

Synthesis of Nanocells for Dual Drug Delivery using PLGA Conjugation

This research outlines the synthesis process of nanocells for dual drug delivery, encapsulating Doxorubicin and 5-FU in PLGA conjugation. It covers the preparation of inner nanoparticles, conjugation of drugs, formation of outer nanocores, lipid envelope preparation, and physicochemical release kinetics studies.

caldwellj
Download Presentation

Synthesis of Nanocells for Dual Drug Delivery using PLGA Conjugation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Synthesis of Nanocells Titima Songkroh Mahidol University

  2. Synthesis ofNanocells Synthesis of the inner nanoparticles (NP) Conjugation of Doxorubicin to PLGA Conjugation of 5-FU to PLGA Synthesis of the outer nanocores

  3. 100 nm Synthesis of the inner NP • contains the first therapeutic agents(Doxorubicin, 5-FU) encapsulated in a polymeric matrix (PLGA) by conjugation

  4. Conjugation of Doxorubicin/5-FU to PLGA Dissolve PLGA 1.5 g in 15 mL CH2Cl2 Add 14 mg of p-NC and 9.4 mg of pyridine Stir at 0°C at RT for 3 h under N2 Dilute with CH2Cl2

  5. * Wash with 0.1% HCl and brine solution Dry on anh.Mg2SO4 Filter Evaporate Obtain activated PLGA polymer * This picture was taken from http://www.rtpumps.com/rtpumps/web/home.nsf/contentview/949D0D491E891025C1256F9000350F4C

  6. Dissolve 0.4 g activated PLGA polymer in 3 mL of DMF Add 4 mg Doxorubicin in 4 µL Et3N Stir 24 h at RT under N2 *** Use 1 mg of 5-FU instead of Doxorubicin for making PLGA-5-FU conjugation***

  7. Ppt by adding cold ether Filter and wash ppt with ether and then dry under vacuum Doxorubicin - PLGA, 5-FU - PLGA

  8. **Mechanism of Doxorubicin (DOX) - PLGA**

  9. **Mechanism of 5-FU - PLGA**

  10. * Synthesis & SEM analysis of NP Completely dissolve 50 mg DOX – PLGA in 2.5 mL acetone by stirring 1 h at RT Add MeOH 0.5 mL Emulsify into an aq.soln of PVA (0.5g/25mL) by slow injection with constant homogenization using a tissue homogenizer * This picture was taken from http://www.eberbachlabtools.com/2355.cfm

  11. * ‡ These pictures were taken from * http://biosurplus.com/inventory.asp?PageNum=4 Sonicate 1 min Add to a dilute aq.soln of PVA (0.2g/100 mL) With rapid mixing for 3 h at RT Ultracentrifuge at 10000, 25000 and 50000 xg Get the smallest NP size fractions ‡ http://www.snupharm.ac.kr/hanbh/about/about_03.asp

  12. * ‡ Extrude through a 100 nm membrane using hand-held extruder Obtain NP for encapsulation within NC Analyze morphology by SEM at a magnification of 3700X These pictures were taken from * http://www.mudinmind.com/index.asp?cat=173666 ‡ from Sengupta, S., et al. Temporal targeting of tumour cell and neovasculature with a nano scale delivery system. Nature. (2005) 436, 568-572.

  13. 200 nm Synthesis of the outer nanocores • coated the inner nanoparticles with a lipid and anti-angiogenesis agent (FTY 720) partitioned in the lipid phase to form a nanocell (NC)

  14. Preparation of Lipid envelope for NC • Cholesterol (CHOL) • Egg-phosphatidylcholine (PC) • Distearoylphosphatidylethanolamine – polyethylene glycol (mw 2000) (DSPE-PEG) • Use in ratio of PC:CHOL:DSPE-PEG = 2:1:0.2 molar

  15. * Dissolve 27.5 mg lipid in 2 mL CHCl2 Add 12.5 mg FTY720 in 1 mL CHCl2 Evaporate solvent to create a monolayer lipid/drug film Shake at 65°C for 1 h * This picture was taken fromhttp://www.toshibha.com/products/oven.html

  16. * Resuspend in 1 mL H2O Add NP which containing 250 µg DOX (or 5-FU) Extrude the result suspension through a 200 nm membrane at 65°C using a hand-held extruder to create the lipid vesicles * This picture was taken from http://www.euroresidentes.com/futuro/nanotecnologia/nanotecnologia_noticias.htm

  17. Determine the average vesicle size by dynamic light scattering Sengupta, S., et al. Temporal targeting of tumour cell and neovasculature with a nano scale delivery system. Nature. (2005) 436, 568-572.

  18. Physicochemical release kinetics studies Suspend NC in 1 mL of PBS Seal in a dialysis bag Incubate in 20 mL of PBS buffer at 37°C with gentle shaking This picture was taken from http://web.siumed.edu/ ~bbartholomew/course_material/protein_methods.htm

  19. Take 200 µL aliquots from the incubation medium at predetermined time intervals and stored frozen for analysis Quantify released drug by RP-HPLC using a C18 column (4.5nm x 150nm, Waters), MeCN and H2O as gradient eluents, Dexamethasone as an internal control This picture was taken from http://www.vscht.cz/trp/UTRP-cs/Vyzkum/Vybaveni/HPLC-RP.html

  20. Outer drug Inner drug Sengupta, S., et al. Temporal targeting of tumour cell and neovasculature with a nano scale delivery system. Nature. (2005) 436, 568-572.

  21. 100 nm 200 nm Summary • Nanocells will provided twotherapeutic agents; anti-angiogenesis (FTY 720) in the outer nanocore and cytotoxic agents (Doxorubicin and 5-FU) in the inner nanoparticle

More Related